Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,201
  • Shares Outstanding, K 146,843
  • Annual Sales, $ 24,290 K
  • Annual Income, $ -24,280 K
  • 60-Month Beta 0.49
  • Price/Sales 9.79
  • Price/Cash Flow N/A
  • Price/Book 5.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.47 +3.40%
on 03/07/19
1.69 -10.06%
on 03/21/19
+0.01 (+0.66%)
since 02/22/19
3-Month
1.36 +11.76%
on 12/24/18
1.77 -14.12%
on 01/25/19
+0.08 (+5.56%)
since 12/21/18
52-Week
1.36 +11.76%
on 12/24/18
3.09 -50.81%
on 06/07/18
-0.42 (-21.65%)
since 03/22/18

Most Recent Stories

More News
What Makes Athersys (ATHX) a New Buy Stock

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATHX : 1.52 (-6.17%)
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018

Substantial progress over the year, advancing programs and

ATHX : 1.52 (-6.17%)
Athersys, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Athersys, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM Eastern...

ATHX : 1.52 (-6.17%)
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?

During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

CARA : 18.30 (-6.82%)
CATB : 7.30 (-2.14%)
TLRY : 67.16 (-4.40%)
ATHX : 1.52 (-6.17%)
Athersys to Host Year-End 2018 Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019, and will host a conference call shortly thereafter at 4:30...

ATHX : 1.52 (-6.17%)
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study

Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.

CELG : 88.15 (-1.65%)
AXON : 1.22 (-5.43%)
ATHX : 1.52 (-6.17%)
ADRO : 3.67 (-5.17%)
Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATHX : 1.52 (-6.17%)
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem(R) Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)

Athersys, Inc. (NASDAQ: ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem(R) cell therapy to treat patients who are suffering from...

ATHX : 1.52 (-6.17%)
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem(R) Therapy for Indications in China

Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.'s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization...

ATHX : 1.52 (-6.17%)
Athersys Reports First Quarter 2018 Results

Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended March 31, 2018.

ATHX : 1.52 (-6.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATHX with:

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

2nd Resistance Point 1.74
1st Resistance Point 1.63
Last Price 1.52
1st Support Level 1.46
2nd Support Level 1.40

See More

52-Week High 3.09
Fibonacci 61.8% 2.43
Fibonacci 50% 2.22
Fibonacci 38.2% 2.02
Last Price 1.52
52-Week Low 1.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar